

# TABLE OF CONTENTS

<b>0. Executive Summary .....</b>	<b>10</b>
<b>1. Cardiovascular Diseases .....</b>	<b>12</b>
<b>Introduction.....</b>	<b>12</b>
<b>History of cardiovascular drug delivery.....</b>	<b>12</b>
<b>Overview of cardiovascular disease .....</b>	<b>13</b>
Coronary artery disease.....	13
<i>Angina pectoris.....</i>	13
<i>Limitations of current therapies for myocardial ischemic disease .....</i>	<i>13</i>
Cardiomyopathies .....	13
Cardiac arrhythmias .....	14
Congestive heart failure.....	14
Peripheral arterial disease .....	14
<i>Current management .....</i>	<i>15</i>
Atherosclerosis .....	15
The endothelium as a target for cardiovascular therapeutics.....	15
<b>Molecular cardiology .....</b>	<b>16</b>
Cardiogenomics .....	16
Cardioproteomics .....	16
<b>Personalized cardiology .....</b>	<b>17</b>
Pharmacogenomics of cardiovascular disorders .....	17
Modifying the genetic risk for myocardial infarction .....	18
Management of heart failure.....	18
Management of hypertension.....	19
<i>Pharmacogenomics of diuretic drugs.....</i>	<i>19</i>
<i>Pharmacogenomics of ACE inhibitors .....</i>	<i>19</i>
<i>Management of hypertension by personalized approach .....</i>	<i>20</i>
Pharmacogenetics of lipid-lowering therapies.....	20
<i>Polymorphisms in genes involved in cholesterol metabolism .....</i>	<i>20</i>
<i>Role of eNOS gene polymorphisms .....</i>	<i>21</i>
<b>Important advances in cardiovascular therapeutics.....</b>	<b>21</b>
<b>Drug delivery, biotechnology and the cardiovascular system.....</b>	<b>22</b>
<b>Role of cardiovascular imaging in cardiovascular therapeutics .....</b>	<b>22</b>
<b>Chronopharmacotherapy of cardiovascular diseases .....</b>	<b>22</b>
<b>2. Methods for Drug Delivery to the Cardiovascular System .....</b>	<b>24</b>
<b>Introduction.....</b>	<b>24</b>
<b>Routes of drug delivery to the cardiovascular system .....</b>	<b>24</b>
<b>Local administration of drugs to the cardiovascular system .....</b>	<b>24</b>
Intramyocardial drug delivery.....	24
Drug delivery via coronary venous system .....	25
Intrapericardial drug delivery .....	25
<b>Formulations for drug delivery to the cardiovascular system.....</b>	<b>26</b>
Sustained and controlled release.....	26
<i>Programming the release at a defined time .....</i>	<i>27</i>
<i>Dosage formulation of calcium channel blockers.....</i>	<i>27</i>
<i>Sustained and controlled release verapamil .....</i>	<i>27</i>
Methods of administration of proteins and peptides .....	27
<i>Delivery of peptides by subcutaneous injection .....</i>	<i>28</i>
<i>Depot formulations and implants.....</i>	<i>28</i>
<i>Poly(ethylene glycol) technology .....</i>	<i>28</i>
<i>Liposomes for cardiovascular drug delivery .....</i>	<i>29</i>
<i>Microencapsulation for protein delivery .....</i>	<i>29</i>
<i>Localized delivery of biomaterials for tissue engineering.....</i>	<i>29</i>
<i>Oral delivery of proteins and peptides.....</i>	<i>29</i>
<b>DDS to improve systemic delivery of cardiovascular drugs .....</b>	<b>31</b>
Nanotechnology-based drug delivery .....	31
Controlled delivery of nanoparticles to injured vasculature .....	32
Nanoparticles for cardiovascular imaging and targeted drug delivery .....	33
Nanofiber-based scaffolds with drug-release properties.....	33
<b>Targeted drug delivery to the cardiovascular system.....</b>	<b>34</b>
Immunotargeting of liposomes to activated vascular endothelial cells .....	34
PEGylated biodegradable particles targeted to inflamed endothelium .....	35
<b>Devices for cardiovascular drug delivery .....</b>	<b>35</b>
Local drug delivery by catheters .....	36
Microneedle for periarterial injection.....	37
Nanotechnology-based devices for the cardiovascular system.....	38

<i>Liposomal nanodevices for targeted cardiovascular drug delivery</i> .....	38
<i>Nanotechnology approach to the problem of "vulnerable plaque"</i> .....	39
<b>Drug delivery in the management of cardiovascular disease</b> .....	<b>39</b>
Drug delivery in the management of hypertension .....	39
<i>Transnasal drug delivery for hypertension</i> .....	40
<i>Transdermal drug delivery for hypertension</i> .....	40
<i>Oral extended and controlled release preparations for hypertension</i> .....	41
<i>Long-acting hypertensives for 24 h blood pressure control</i> .....	42
<i>Drug delivery to control early morning blood pressure peak</i> .....	42
<i>Role of drug delivery in improving compliance with antihypertensive therapy</i> .....	43
Drug delivery for congestive heart failure .....	43
<i>Oral human brain-type natriuretic peptide</i> .....	43
<i>Nitric oxide-based therapies for congestive heart failure</i> .....	43
<i>Automated drug delivery system for cardiac failure</i> .....	44
DDS in the management of ischemic heart disease .....	44
<i>Intravenous emulsified formulations of halogenated anesthetics</i> .....	45
<i>Injectable peptide nanofibers for myocardial ischemia</i> .....	45
<i>Delivery of angiogenesis-inducing agents for myocardial ischemia</i> .....	46
Drug delivery for cardioprotection .....	46
Drug delivery for cardiac rhythm disorders .....	47
Drug delivery in the treatment of angina pectoris .....	48
<i>Sustained and controlled-release nitrate for angina pectoris</i> .....	48
<i>Transdermal nitrate therapy</i> .....	48
<i>Controlled release calcium blockers for angina pectoris</i> .....	50
Vaccines for hypertension .....	50
Drug delivery in the management of pulmonary hypertension .....	50
<i>Prostacyclin by inhalation</i> .....	51
<i>Endothelin receptor antagonist treatment of PAH</i> .....	51
Anticoagulation in cardiovascular disease .....	51
<i>Oral heparin</i> .....	51
<i>Low molecular weight heparin-loaded polymeric nanoparticles</i> .....	52
<i>Transdermal anticoagulants</i> .....	52
Thrombolysis for cardiovascular disorders .....	52
<i>Use of ultrasound to facilitate thrombolysis</i> .....	53
<i>Delivery of alteplase through the AngioJet rheolytic catheter</i> .....	53
Drug delivery for peripheral arterial disease .....	53
<i>Delivery of thrombolytic agent to the clot through a catheter</i> .....	54
<i>Delivery of growth factors to promote angiogenesis in ischemic limbs</i> .....	54
<i>Immune modulation therapy for PAD</i> .....	54
<i>NO-based therapies for peripheral arterial disease</i> .....	54
Drug delivery in the management of hypercholesterolemia .....	55
<i>Controlled/sustained release formulations of statins</i> .....	55
<i>Combinations of statins with other drugs to increase efficacy</i> .....	55
<i>Controlled release fenofibrate</i> .....	56
<i>Extended release nicotinic acid</i> .....	57
<i>Intravenous infusion of lipoprotein preparations to raise HDL</i> .....	58
<i>Innovative approaches to hypercholesterolemia</i> .....	58
Single dose therapy for more than one cardiovascular disorder .....	58
<b>3. Cell Therapy for Cardiovascular Disorders</b> .....	<b>60</b>
<b>Introduction</b> .....	<b>60</b>
Inducing the proliferation of cardiomyocytes .....	60
Role of stem cells in repair of the heart .....	60
Cell-mediated immune modulation for chronic heart disease .....	60
Cell therapy for atherosclerotic coronary artery disease .....	61
Transplantation of myoblasts for myocardial infarction .....	61
<i>MyoCell™ (Bioheart)</i> .....	62
Transplantation of cardiac progenitor cells for revascularization of myocardium .....	63
<b>Methods of delivery of cells to the heart</b> .....	<b>63</b>
Cellular cardiomyoplasty .....	63
IGF-1 delivery by nanofibers to improve cell therapy for MI .....	64
Intracoronary infusion of bone marrow-derived cells for AMI .....	64
Non-invasive delivery of cells to the heart by Morph@guide catheter .....	64
Transplantation of stem cells for myocardial infarction .....	65
<i>Transplantation of embryonic stem cells</i> .....	65
<i>Transplantation of hematopoietic stem cells</i> .....	65
<i>Transplantation of cord blood stem cells for myocardial infarction</i> .....	65
<i>Intracoronary infusion of mobilized peripheral blood stem cells</i> .....	66
<i>Human mesenchymal stem cells for cardiac regeneration</i> .....	66
<i>Cytokine preconditioning of human fetal liver CD133+ SCs</i> .....	67
<i>Transplantation of expanded adult SCs derived from the heart</i> .....	67

<i>Transplantation of endothelial cells</i> .....	67
Transplantation of genetically modified cells .....	68
<i>Transplantation of cells secreting vascular endothelial growth factor</i> .....	68
<i>Transplantation of genetically modified bone marrow stem cells</i> .....	68
Cell transplantation for congestive heart failure .....	68
<i>Injection of adult stem cells for congestive heart failure</i> .....	68
<i>Intracoronary infusion of cardiac stem cells</i> .....	69
<i>Myoblasts for treatment of congestive heart failure</i> .....	69
Role of cell therapy in cardiac arrhythmias .....	69
<i>Atrioventricular conduction block</i> .....	70
<i>Ventricular tachycardia</i> .....	70
<i>ESCs for correction of congenital heart defects</i> .....	71
Cardiac progenitors cells for treatment of heart disease in children .....	71
Stem cell therapy for peripheral arterial disease .....	72
Targeted delivery of endothelial progenitor cells labeled with nanoparticles .....	72
Clinical trials of cell therapy in cardiovascular disease.....	72
A critical evaluation of cell therapy for heart disease .....	74
Publications of clinical trials of cell therapy for CVD .....	75
<b>Future directions for cell therapy of CVD .....</b>	<b>75</b>

#### **4. Gene Therapy for Cardiovascular Disorders ..... 78**

<b>Introduction.....</b>	<b>78</b>
<b>Techniques of gene transfer to the cardiovascular system.....</b>	<b>79</b>
Direct plasmid injection into the myocardium .....	79
Catheter-based systems for vector delivery .....	79
Ultrasound microbubbles for cardiovascular gene delivery .....	80
Vectors for cardiovascular gene therapy.....	80
<i>Adenoviral vectors for cardiovascular diseases</i> .....	80
<i>Intravenous rAAV vectors for targeted delivery to the heart</i> .....	81
<i>Plasmid DNA-based delivery in cardiovascular disorders</i> .....	81
Hypoxia-regulated gene therapy for myocardial ischemia .....	81
Angiogenesis and gene therapy of ischemic disorders .....	82
Therapeutic angiogenesis vs. vascular growth factor therapy .....	82
Gene painting for delivery of targeted gene therapy to the heart.....	83
Gene delivery to vascular endothelium .....	83
Targeted plasmid DNA delivery to the cardiovascular system with nanoparticles .....	83
Gene delivery by vascular stents.....	84
<b>Gene therapy for genetic cardiovascular disorders .....</b>	<b>84</b>
Genetic disorders predisposing to atherosclerosis.....	84
Familial hypercholesterolemia.....	85
Apolipoprotein E deficiency.....	86
Hypertension .....	86
Genetic factors for myocardial infarction .....	87
<b>Acquired cardiovascular diseases .....</b>	<b>87</b>
Coronary artery disease with angina pectoris.....	87
<i>Ad5FGF-4</i> .....	87
Ischemic heart disease with myocardial infarction .....	88
<i>Angiogenesis for cardiovascular disease</i> .....	88
<i>Myocardial repair with IGF-1 therapy</i> .....	89
<i>miRNA gene therapy for ischemic heart disease</i> .....	90
Congestive heart failure.....	90
<i>Rationale of gene therapy in CHF</i> .....	90
<i><math>\beta</math>-ARKct gene therapy</i> .....	90
<i>Intracoronary adenovirus-mediated gene therapy for CHF</i> .....	91
<i>AAV-mediated gene transfer for CHF</i> .....	91
<i>AngioCell gene therapy for CHF</i> .....	92
<i>nNOS gene transfer in CHF</i> .....	92
Gene therapy for cardiac arrhythmias .....	92
<i>Gene transfer for biological pacemakers</i> .....	93
<i>Management of arrhythmias due to myoblast transplantation</i> .....	94
<i>Genetically engineered cells as biological pacemakers</i> .....	94
Gene therapy and heart transplantation .....	94
Gene therapy for peripheral arterial disease .....	95
<i>Angiogenesis by gene therapy</i> .....	95
<i>HIF-1<math>\alpha</math> gene therapy for peripheral arterial disease</i> .....	95
<i>HGF gene therapy for peripheral arterial disease</i> .....	96
<i>Ischemic neuropathy secondary to peripheral arterial disease</i> .....	96
Maintaining vascular patency after surgery.....	96
<b>Antisense therapy for cardiovascular disorders .....</b>	<b>97</b>
Antisense therapy for hypertension .....	98
Antisense therapy for hypercholesterolemia .....	98

<b>RNAi for cardiovascular disorders .....</b>	<b>99</b>
RNAi for hypercholesterolemia .....	99
microRNA and the cardiovascular system .....	100
<i>Role of miRNAs in angiogenesis .....</i>	<i>100</i>
<i>Role of miRNAs in cardiac hypertrophy and failure.....</i>	<i>100</i>
<i>Role of miRNAs in conduction and rhythm disorders of the heart.....</i>	<i>101</i>
<i>miRNA-based approach for reduction of hypercholesterolemia .....</i>	<i>101</i>
<i>miRNAs as therapeutic targets for cardiovascular diseases .....</i>	<i>102</i>
<i>Future prospects of miRNA in the cardiovascular therapeutics.....</i>	<i>102</i>
<b>Future prospects of gene therapy of cardiovascular disorders .....</b>	<b>102</b>
<b>Companies involved in gene therapy of cardiovascular disorders .....</b>	<b>103</b>

## **5. Drug-Eluting Stents ..... 106**

<b>Introduction.....</b>	<b>106</b>
Percutaneous transluminal coronary angioplasty .....	106
Stents .....	106
<b>Restenosis .....</b>	<b>106</b>
Pathomechanism.....	107
Treatment.....	107
Nitric oxide-based therapies for restenosis .....	108
Carbon monoxide inhalation for preventing restenosis .....	108
Antisense approaches for prevention of restenosis after angioplasty .....	109
miRNA-based approach for restenosis following angioplasty .....	110
Gene therapy to prevent restenosis after angioplasty .....	110
<i>Techniques of gene therapy for restenosis.....</i>	<i>111</i>
<i>NOS gene therapy for restenosis.....</i>	<i>112</i>
<i>Nonviral gene therapy to prevent intimal hyperplasia .....</i>	<i>112</i>
<i>HSV-1 gene therapy to prevent intimal hyperplasia .....</i>	<i>113</i>
Drug delivery devices for restenosis .....	113
Local drug delivery by catheter.....	113
Stenosis associated with stents.....	114
Absorbable metal stents .....	114
<b>Drug-eluting stents.....</b>	<b>114</b>
Various types of DES .....	115
<i>CYPHER® sirolimus-eluting coronary stent.....</i>	<i>115</i>
<i>Dexamethasone-eluting stents.....</i>	<i>115</i>
<i>NO-generating stents .....</i>	<i>116</i>
<i>Paclitaxel-eluting stents.....</i>	<i>116</i>
<i>Sirolimus-eluting vs paclitaxel-eluting stents .....</i>	<i>117</i>
Novel technologies for DES .....	117
<i>Absorbable DES .....</i>	<i>117</i>
<i>Bio-absorbable low-dose DES .....</i>	<i>118</i>
<i>Drug-eluting stents coated with polymer surfaces .....</i>	<i>118</i>
<i>Endeavour DES.....</i>	<i>118</i>
<i>Stents for delivery of gene therapy .....</i>	<i>119</i>
<i>Stem cell-based stents .....</i>	<i>120</i>
<i>VAN 10-4 DES .....</i>	<i>120</i>
Nanotechnology-based stents .....	121
<i>Drugs encapsulated in biodegradable nanoparticles .....</i>	<i>121</i>
<i>Magnetic nanoparticle-coated DES .....</i>	<i>121</i>
<i>Magnetic nanoparticles encapsulating paclitaxel targeted to stents .....</i>	<i>122</i>
<i>Nanocoated DES .....</i>	<i>122</i>
<i>Nanopores to enhance compatibility of DES.....</i>	<i>123</i>
<i>Paclitaxel-encapsulated targeted lipid-polymeric nanoparticles.....</i>	<i>123</i>
The ideal DES .....	123
Companies developing drug-eluting stents .....	124
Clinical trials of drug-eluting stents .....	125
<i>Measurements used in clinical trials of DES .....</i>	<i>125</i>
<i>TAXUS paclitaxel-eluting stents.....</i>	<i>125</i>
<i>XIENCE™ V everolimus-eluting coronary stent.....</i>	<i>126</i>
<i>COSTAR II clinical trial.....</i>	<i>127</i>
<i>Endeavor RESOLUTE zotarolimus-eluting stent system.....</i>	<i>127</i>
<i>CUSTOM I clinical trial .....</i>	<i>128</i>
<i>NOBORI CORE Trial .....</i>	<i>128</i>
<i>LEADERS trial .....</i>	<i>129</i>
<i>Comparison of DES in clinical trials.....</i>	<i>129</i>
Comparison of DES with competing technologies.....	130
<i>DES versus coronary artery bypass graft.....</i>	<i>130</i>
<i>DES versus bare metal stents.....</i>	<i>130</i>
<i>Multi-Link Vision bare metal stent vs DES .....</i>	<i>133</i>
<i>Guidelines for DES vs BMS .....</i>	<i>133</i>

<i>DES vs BMS for off-label indications</i> .....	133
<i>Role of DES in cases of bare-metal in-stent restenosis</i> .....	134
<i>DES versus balloon catheter coated with paclitaxel</i> .....	134
<i>DES versus intracoronary radiation therapy for recurrent stenosis</i> .....	134
Cost-effectiveness of DES .....	135
Safety issues of DES .....	136
<i>Adverse reactions to DES</i> .....	136
<i>Endothelial vascular dysfunction due to sirolimus</i> .....	136
<i>Risk of clotting with DES</i> .....	136
<i>Clopidogrel use and long-term outcomes of patients receiving DES</i> .....	138
<i>Prasugrel as antiplatelet agent</i> .....	138
<i>Effect of blood clot on release of drug from DES</i> .....	139
<i>Use of magnetized cell lining to prevent clotting of DES</i> .....	139
<i>Long-term safety studies of DES</i> .....	139
<b>Regulatory issues of DES</b> .....	<b>140</b>
<b>Future prospects for treatment of restenosis by DES</b> .....	<b>142</b>
Future role of DES in management of cardiovascular diseases .....	142
Stent cost and marketing strategies .....	143
Improvements in stent technology .....	143
<i>Bioabsorbable stent</i> .....	143
DES vs drug-eluting balloons .....	144
<b>6. Markets for Cardiovascular Drug Delivery</b> .....	<b>146</b>
<b>Introduction</b> .....	<b>146</b>
<b>Epidemiology of cardiovascular disease</b> .....	<b>146</b>
<b>Cost of care of cardiovascular disorders</b> .....	<b>147</b>
<b>Cardiovascular markets according to important diseases</b> .....	<b>148</b>
Antithrombotics .....	148
Anticholesterol agents .....	148
Antihypertensive agents .....	149
Drugs for congestive heart failure .....	149
<b>Markets for innovative technologies for cardiovascular disorders</b> .....	<b>149</b>
Markets for cell therapy of cardiovascular disorders .....	149
Markets for gene therapy of cardiovascular disorders .....	150
Markets for drug-eluting stents .....	150
<i>Major players in DES market</i> .....	150
<i>Impact of safety issues on future markets for DES</i> .....	150
<i>DES market in Asia</i> .....	151
<i>Patenting and legal issues of DES</i> .....	152
<i>The financial impact of DES on cardiovascular markets</i> .....	152
<b>Unmet needs for cardiovascular drug delivery</b> .....	<b>153</b>
<b>Role of DDS in developing cardiovascular markets</b> .....	<b>154</b>
Markets for cardiovascular devices .....	154
Marketing of innovative cardiovascular drug delivery devices .....	154
Direct to consumer advertising of DES .....	155
Future trends in the integration of drug delivery with therapeutics .....	155
Future prospects of cardiovascular drug delivery .....	155
<b>7. Companies involved in Cardiovascular Drug Delivery</b> .....	<b>156</b>
<b>Profiles of companies</b> .....	<b>156</b>
<b>Collaborations</b> .....	<b>242</b>
<b>8. References</b> .....	<b>246</b>

## Tables

Table 1-1: Landmarks in the historical evolution of cardiovascular drug delivery .....	12
Table 1-2: Gene polymorphisms that alter cardiovascular response to drugs .....	17
Table 2-1: Routes of drug delivery used for treatment of cardiovascular disorders .....	24
Table 2-2: Formulations for drug delivery to the cardiovascular system .....	26
Table 2-3: Improved methods of systemic drug delivery of cardiovascular drugs .....	31
Table 2-4: Targeted delivery of therapeutic substances to the cardiovascular system .....	34
Table 2-5: Classification of devices for drug delivery to the cardiovascular system .....	35
Table 2-6: Various methods of delivery of therapeutic agents for hypertension .....	40
Table 2-7: Marketed controlled/ extended release preparation for hypertension .....	42
Table 2-8: Drug delivery in ischemic heart disease .....	44
Table 2-9: Methods of delivery of nitrate therapy in angina pectoris .....	48
Table 2-10: Drug delivery for peripheral arterial disorders .....	53
Table 3-1: Clinical trials of cell therapy in cardiovascular disease .....	72

Table 4-1: Cardiovascular disorders for which gene therapy is being considered.....	78
Table 4-2: Catheter-based systems for vector delivery to the cardiovascular system.....	79
Table 4-3: Potential applications of antisense in cardiovascular disorders.....	98
Table 4-4: Companies involved in gene therapy of cardiovascular diseases.....	103
Table 5-1: Treatment of restenosis.....	107
Table 5-2: Devices used for drug delivery in restenosis.....	113
Table 5-3: Companies involved in drug-eluting stents.....	124
Table 6-1: Prevalence of cardiovascular disorders in major markets: US 2011-2021.....	147
Table 6-2: Prevalence of cardiovascular disorders in major markets: Europe 2011-2021.....	147
Table 6-3: Prevalence of cardiovascular disorders in major markets: Japan 2011-2021.....	147
Table 6-4: Values of cardiovascular DDS in major markets 2011-2021.....	148
Table 6-5: Markets for innovative technologies for cardiovascular disorders 2011-2021.....	149
Table 7-1: Top 5 companies in cardiovascular drug delivery.....	156
Table 7-2: Collaborations in cardiovascular drug delivery.....	242

## **Figures**

Figure 1-1: Drug delivery, biotechnology and cardiovascular diseases.....	22
Figure 2-1: MicroSyringe for periarterial injection.....	38
Figure 5-1: Vicious circle of vascular occlusion following angioplasty and stenting.....	108
Figure 5-2: Measurement of in-stent stenosis.....	114
Figure 5-3: Medtronic's Endeavour drug-eluting stent.....	119
Figure 5-4: Magnetic nanoparticle-coated stent.....	122
Figure 6-1: Unmet needs for cardiovascular drug delivery.....	153